FairValu
THERMO FISHER SCIENTIFIC INC.

THERMO FISHER SCIENTIFIC INC.

TMONYSE

Diagnostics & Research • Healthcare

Current Price
$622.180.00%
Market Cap
$230.05B
Shares Outstanding: 369.75M
Volume
-
Avg Vol (3M): -
Next Earnings
-
52 Week Range
Low: $--High: $--

Comprehensive AI Analysis

Strategic AI Analysis for TMO

Checking whether the approved providers contain enough current financial data for a reliable report.

Summary

Source-linked company research for TMO

Factor Scorecard

Mechanical 0-100 composites from the displayed inputs. Bands and colours are numerical aids, not security ratings or investment actions.

22/31 signals active· low confidence at 70% coverage
Overall Factor Score
6055-69 band
Growth
5555-69 band
Quality
7570-84 band
Valuation
290-39 band
Financial Health
7970-84 band

Latest results at a glance

Insights from the latest company results and reports · filed 23 Jul 2026

  • Q2 Revenue and EPS Growth

    Second-quarter 2026 revenue grew 10% to $11.99 billion, with organic revenue growth of 5% compared to the same quarter in 2025.

  • Earnings Exceed Consensus

    Reported adjusted EPS of $6.03 per share for the quarter ended June 30, 2026, exceeded the same-quarter consensus estimate of $5.71.

  • Operating Margin Expansion

    Adjusted operating margin reached 22.8% in the second quarter of 2026, up from 21.9% in the second quarter of 2025.

  • Capital Return Coverage

    Free cash flow of $6.293 billion in the fiscal year ended 2025 was 2.10 times the $3 billion in common stock repurchases.

AI-generated · updated 28 Aug 2026View source filing

Price Chart

NYSE:TMO via TradingView

Loading TradingView chart...

Overview

Quarterly income statement data isn't available for this company.

No Data

No annual financial data available.

Financial Fundamentals

Growth, quality, valuation, cash generation, and balance-sheet strength.

Sector: Healthcare

Growth

TTM revenue plus current, long-term, forward, and accelerating top-line trends.

Revenue
-
Revenue Growth
7.2%
Moderate
Revenue CAGR 3Y
-
Forward Revenue Growth
7.4%
Moderate
Revenue Acceleration
5.2%
Improving

Earnings

Trailing EPS, current EPS growth, long-term compounding, surprise, and forward expectations.

EPS (TTM)
18.83
Profitable
EPS Growth
5.8%
Moderate
EPS CAGR 3Y
-
EPS Surprise
5.6%
Beat
Forward EPS
25.12
Profitable
Fwd Revenue Growth
7.4%
Forward EPS Growth
9.5%
Moderate

Profitability

TTM margin and return metrics that reflect pricing power and business quality.

Gross Margin
-
Operating Margin
17.6%
High
Net Margin
15.0%
High
ROE
13.2%
Good
ROIC
14.4%
Strong

Cash Flow

TTM free cash flow, growth, margin, and operating-cash conversion quality.

Free Cash Flow
$7.32B
Positive
FCF Growth
18.6%
Strong
FCF Margin
-
Cash Conversion
1.29x
Excellent

Valuation

Metrics ranked by issuer type, financial state, and input quality.

Established companyPrimary lens

Forward P/E

Forward P/E is the primary lens because positive expected earnings make the next operating period directly assessable.

Forward P/EPrimary
24.77x
High
EV / EBITDASupporting
24.66x
High
EV / FCFSupporting
31.34x
High
Trailing P/ESupporting
33.04x
High

Financial Health

Latest-quarter liquidity and leverage checks plus TTM interest coverage.

Current Ratio
1.55x
Healthy
Quick Ratio
0.90x
Adequate
Debt / Equity
0.06x
Conservative
Interest Coverage
-

Shareholder Signals

Capital returns and dilution checks sourced from statements and insider filings.

Dividend Yield
0.3%
Low/None
Payout Ratio
9.5%
Sustainable
Buyback Yield
2.2%
Positive
Net Insider Buys
-36
Selling

Peer Comparison

TickerPrice
TMOTHERMO FISHER SCIENTIFIC INC.
$622.18
Company Profile

About the Company

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Next Earnings Date

Oct 21, 2026

Loading latest news...